Neuberger Berman Group’s Pacific Biosciences PACB Stock Holding History

Neuberger Berman Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34K	Sell	20,251 -10,690	-35%	-$15.5K	﹤0.01%	2308
2026 Q1	$40.8K	Buy	30,941 +9,506	+44%	+$17K	﹤0.01%	2124
2025 Q4	$40.1K	Buy	+21,435	New	+$41.2K	﹤0.01%	2063
2025 Q1	–	Sell	-28,208	Closed	-$51.6K	–	2033
2024 Q4	$51.6K	Buy	28,208 +892	+3%	+$1.74K	﹤0.01%	1881
2024 Q3	$46.4K	Buy	+27,316	New	+$44.9K	﹤0.01%	1874
2024 Q1	–	Sell	-1,243,542	Closed	-$12.2M	–	1899
2023 Q4	$12.2M	Buy	1,243,542 +765,432	+160%	+$6.26M	0.01%	868
2023 Q3	$3.99M	Buy	478,110 +65,361	+16%	+$747K	﹤0.01%	929
2023 Q2	$5.49M	Buy	+412,749	New	+$5.02M	﹤0.01%	864

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Neuberger Berman Group's PACB Position: Q2 2026 in Review

Neuberger Berman Group reduced its Pacific Biosciences (PACB) stake by 35% in Q2 2026, selling an estimated $15.5K and leaving 20,251 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #2308.

Neuberger Berman Group first reported a position in PACB in Q2 2023 and has held it in 8 quarters since. The position peaked at $12.2M in Q4 2023. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Neuberger Berman Group held 20,251 shares of Pacific Biosciences worth $34K as of Q2 2026.
Neuberger Berman Group sold 10,690 Pacific Biosciences shares in Q2 2026, an estimated $15.5K.
Pacific Biosciences made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2308 holding.
Neuberger Berman Group first reported a position in Pacific Biosciences in Q2 2023 and has held it in 8 quarters since.
Neuberger Berman Group's Pacific Biosciences position peaked at $12.2M in Q4 2023.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.